|
MXPA04008671A
(es)
*
|
2002-03-08 |
2004-12-06 |
Lilly Co Eli |
Derivados de pirrol-2,5-diona y su uso como inhibidores de gsk-3.
|
|
GB0212049D0
(en)
*
|
2002-05-24 |
2002-07-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
ATE486872T1
(de)
|
2005-02-09 |
2010-11-15 |
Arqule Inc |
Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
|
|
US20080207594A1
(en)
*
|
2005-05-04 |
2008-08-28 |
Davelogen Aktiengesellschaft |
Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
|
|
WO2006117221A1
(en)
*
|
2005-05-04 |
2006-11-09 |
Develogen Aktiengesellschaft |
Use of azapaullones for preventing and treating pancreatic autoimmune disorders
|
|
EP1928437A2
(en)
|
2005-08-26 |
2008-06-11 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
EP1940389A2
(en)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
TW200800203A
(en)
|
2006-03-08 |
2008-01-01 |
Astrazeneca Ab |
New use
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
AU2007225088B2
(en)
*
|
2006-03-13 |
2012-09-13 |
Kyorin Pharmaceutical Co., Ltd |
Aminoquinolones as GSK-3 inhibitors
|
|
EP1845098A1
(en)
|
2006-03-29 |
2007-10-17 |
Ferrer Internacional, S.A. |
Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
|
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
JP2010500300A
(ja)
|
2006-08-08 |
2010-01-07 |
サノフィ−アベンティス |
アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
CN101302216B
(zh)
*
|
2007-05-11 |
2011-08-10 |
上海睿智化学研究有限公司 |
稠环吲哚类化合物的制备方法
|
|
AU2008268613A1
(en)
|
2007-06-22 |
2008-12-31 |
Arqule, Inc. |
Quinazolinone compounds and methods of use thereof
|
|
EP2392574B1
(en)
|
2007-06-22 |
2013-12-18 |
ArQule, Inc. |
Indolyl pyrrolidines for the treatment of cancer
|
|
WO2009002806A1
(en)
|
2007-06-22 |
2008-12-31 |
Arqule, Inc. |
Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
|
|
TWI428132B
(zh)
*
|
2007-07-02 |
2014-03-01 |
Lilly Co Eli |
癌症化療效果之強化
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
PL2315756T3
(pl)
*
|
2008-07-08 |
2015-02-27 |
Incyte Holdings Corp |
1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
|
|
WO2010003624A2
(en)
|
2008-07-09 |
2010-01-14 |
Sanofi-Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
CA2758473C
(en)
|
2009-04-14 |
2013-12-17 |
Eli Lilly And Company |
Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
|
|
MX2012001729A
(es)
|
2009-08-26 |
2012-06-13 |
Sanofi Sa |
Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
|
|
PH12012500778A1
(en)
|
2009-10-30 |
2012-11-26 |
Janssen Pharmaceutica Nv |
IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
|
|
WO2011082266A2
(en)
|
2009-12-30 |
2011-07-07 |
Arqule, Inc. |
Substituted heterocyclic compounds
|
|
WO2011089416A1
(en)
|
2010-01-19 |
2011-07-28 |
Astrazeneca Ab |
Pyrazine derivatives
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
AR080754A1
(es)
|
2010-03-09 |
2012-05-09 |
Janssen Pharmaceutica Nv |
Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
|
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
JP5984837B2
(ja)
*
|
2010-12-23 |
2016-09-06 |
アークル インコーポレイテッド |
ピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにそれを調製および使用する方法
|
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683698B1
(de)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683701B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
BR112013033375B1
(pt)
|
2011-06-27 |
2022-05-10 |
Janssen Pharmaceutica N.V |
Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
HK1206250A1
(en)
|
2012-06-26 |
2016-01-08 |
Janssen Pharmaceutica Nv |
Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders
|
|
WO2014009305A1
(en)
|
2012-07-09 |
2014-01-16 |
Janssen Pharmaceutica Nv |
Inhibitors of phosphodiesterase 10 enzyme
|
|
WO2014098000A1
(en)
*
|
2012-12-17 |
2014-06-26 |
Daiichi Sankyo Company, Limited |
Process for preparation of a tricyclic heterocycle
|
|
TW201506010A
(zh)
|
2013-06-26 |
2015-02-16 |
Daiichi Sankyo Co Ltd |
三環雜環化合物之製造方法
|
|
EP2818471A1
(en)
*
|
2013-06-27 |
2014-12-31 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
|
|
US11066419B2
(en)
*
|
2016-12-30 |
2021-07-20 |
Frequency Therapeutics, Inc. |
1H-pyrrole-2,5-dione compounds and methods of using same
|
|
AU2018250591A1
(en)
|
2017-04-11 |
2019-10-10 |
Frequency Therapeutics, Inc. |
Methods for hair follicle stem cell proliferation
|
|
WO2019126686A1
(en)
*
|
2017-12-21 |
2019-06-27 |
Frequency Therapeutics, Inc. |
1,2-dihydro-3h-pyrazol-3-one compounds and methods of using same
|
|
US10526343B2
(en)
|
2018-03-26 |
2020-01-07 |
University Of Sharjah |
Heterocyclic systems and pharmaceutical applications thereof
|
|
US12448374B2
(en)
|
2018-06-07 |
2025-10-21 |
Disarm Therapeutics, Inc. |
Inhibitors of SARM1
|
|
KR102919209B1
(ko)
|
2018-08-10 |
2026-01-28 |
다이아핀 테라퓨틱스, 엘엘씨 |
트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료
|
|
US20200121681A1
(en)
|
2018-10-17 |
2020-04-23 |
Frequency Therapeutics, Inc. |
Methods for hair follicle stem cell proliferation
|
|
WO2020132045A1
(en)
|
2018-12-19 |
2020-06-25 |
Disarm Therapeutics, Inc. |
Inhibitors of sarm1 in combination with neuroprotective agents
|
|
EP3920885A1
(en)
|
2019-02-08 |
2021-12-15 |
Frequency Therapeutics, Inc. |
Valproic acid compounds and wnt agonists for treating ear disorders
|
|
CN112390794B
(zh)
*
|
2019-08-19 |
2023-05-26 |
鲁南制药集团股份有限公司 |
一种米诺膦酸关键中间体的制备方法
|
|
CN115925622B
(zh)
*
|
2023-02-10 |
2025-04-22 |
山西永津集团有限公司 |
一种3-氰基吡啶-2-基氨基甲酸叔丁酯的合成方法
|
|
CN115974850B
(zh)
*
|
2023-02-16 |
2024-08-06 |
中国药科大学 |
一类作为akr1c3抑制剂的化合物及其制备方法与用途
|